Join DDW for this free event, ‘CRISPR screening at scale: Achieving 1M cell data sets with an instrument-free, cost-effective approach‘, which is supported by Scale Biosciences. The event will take place on 25 April 5 PM BST / 6PM CEST / 9AM PST. Read More
Join DDW for this free event, ‘CRISPR screening at scale: Achieving 1M cell data sets with an instrument-free, cost-effective approach‘, which is supported by Scale Biosciences. The event will take place on 25 April 5 PM BST / 6PM CEST / 9AM PST. Read More
Join DDW for this free event, ‘CRISPR screening at scale: Achieving 1M cell data sets with an instrument-free, cost-effective approach‘, which is supported by Scale Biosciences. The event will take place on 25 April 5 PM BST / 6PM CEST / 9AM PST. Read More
Pooled CRISPR screens offer the ability to knock out or perturb many genes in a single experiment from several hundred to tens of thousands of targets in parallel. Genome-wide screens are becoming the standard for drug discovery to power unbiased identification of drug targets across gene regulatory networks. Requiring single-cell… Read More
Researchers from Japan have used CRISPR gene editing to enhance the effectiveness of rejuvenated cytotoxic T lymphocytes (rejTs) for targeted immunotherapy. RejTs constitute a promising approach for treating cervical cancer, though rejection by the host’s immune system is a major hurdle. In a recent… Read More
Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society1 state that “a little over… Read More
Following the first regulatory approval of a CRISPR-based drug in late 2023, over ten years since the CRISPR-Cas9 system was elucidated, there is considerable optimism about the future potential for gene editing technologies. The astonishing pace of innovation has led to new, potentially safer CRISPR-based techniques, including… Read More
This eBook explores the latest innovations in gene editing and CRISPR, the possibilities of new editing techniques and where the greatest potential for the technology might lie in the future. Download this exclusive eBook to learn more about: How CRISPR is providing new solutions for common diseases; The potential of base editing… Read More
Dr Mike Tarselli, Chief Scientific & Knowledge Officer at TetraScience, was Scientific Director of SLAS until 2020, and will be chairing his first event this year. He shares his insight with Megan Thomas. From pharma to non-profit “I probably wouldn’t have the role I have now if I hadn’t worked… Read More
DDW’s Senior Digital Content Editor Diana Spencer reviews the year’s top ten articles. DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy (CGT) has been a… Read More
The US Food and Drug Administration (FDA) has approved the first cell-based gene therapies for the treatment of sickle cell disease (SCD), Casgevy and Lyfgenia. Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is also the first FDA-approved treatment to use CRISPR gene editing technology. However, the FDA added a black… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The key drug discovery news this week focuses on experimental approaches to… Read More
News round-up for 27 November – 1 December by DDW Digital Content Editor Diana Spencer. The key drug discovery news this week focuses on experimental approaches to the treatment of some of the most challenging diseases, including a mathematical model that can simulate Alzheimer’s progression and… Read More
Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. Using a technique they’ve dubbed “cancer shredding,” the researchers at Gladstone Institutes programmed CRISPR to zero-in on repeating DNA sequences present only… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The breaking news this week was certainly the first regulatory approval for… Read More
News round-up for 13-17 November by DDW Digital Content Editor Diana Spencer. The breaking news this week was certainly the first regulatory approval for Casgevy, not only the first gene therapy approved for sickle cell disease, but also the first therapy to use CRISPR gene editing. Read More
